Summary & Overview
HCPCS Level II J1744: Icatibant Injection, 1 mg
HCPCS Level II code J1744 denotes a 1 mg unit of icatibant for injection, a targeted therapy used in acute management of specific conditions where bradykinin-mediated pathways are implicated. Nationally, accurate coding for biologic injectables like icatibant affects pharmacy spend, billing consistency, and access to specialty therapies. Major commercial and public payers set coverage and reimbursement rules that influence site-of-care decisions and prior authorization practices.
This publication covers payer policies and benchmarks for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an outline of clinical context for icatibant use, common sites of service for administration, and the types of benchmarks and policy updates typically tracked for specialty injectable medications. The report also highlights areas where coding clarity matters for billing teams, such as unit-of-service reporting and billing at the point of care.
Topics addressed include expected service line placement for injectable biologics, common documentation considerations, and a summary of what payers commonly require for coverage determinations. Data not available in the input will be identified as such rather than inferred.
Billing Code Overview
HCPCS Level II code J1744 represents the medication icatibant, billed per 1 mg unit for injection. This code is used when icatibant is administered as a parenteral therapeutic agent.
-
Service type: Injection/Parenteral medication delivery
-
Typical site of service: Ambulatory clinic, outpatient infusion center, emergency department, or other clinical settings where injectable biologic therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting with acute hereditary angioedema (HAE) or an acute angioedema attack characterized by localized, non-pitting edema of the face, extremities, gastrointestinal tract (abdominal pain, vomiting), or upper airway swelling with potential airway compromise. The presenting workflow commonly occurs in an emergency department, urgent care clinic, infusion center, or outpatient specialty clinic where rapid symptom control is required.
A patient arrives with progressive facial swelling and difficulty breathing. After rapid assessment, airway status is monitored and intravenous access is established. The treating clinician (emergency physician, allergist/immunologist, or trained advanced practice provider) documents the diagnosis of acute HAE attack and administers a subcutaneous injection of J1744 (icatibant, 1 mg per unit). Observation follows for clinical response and potential adverse effects, with repeated dosing per product labeling if clinically indicated. Documentation includes indication, lot number, quantity administered (milligrams and total units), route (subcutaneous), site of administration, and any applicable modifier to reflect circumstances (e.g., partial administration, patient left against medical advice). Billing occurs under HCPCS Level II code J1744 with supporting ICD-10 diagnosis and any applicable procedural CPT codes for related services such as evaluation and management or airway management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|